At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 300 enrolled
Drug / intervention
Loteprednol etabonate 0.2% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Clinical Safety and Efficacy Evaluation of Alrex® (Loteprednol Etabonate Ophthalmic Suspension, 0.2%) Versus Patanol (Olopatadine Hydrochloride Ophthalmic Solution, 0.1%) in the Treatment of Seasonal Allergic Conjunctivitis (SAC)
In Brief
A Phase 3 clinical trial evaluating Loteprednol etabonate 0.2% and Olopatadine 0.1% for Seasonal Allergic Conjunctivitis. Completed, enrolled 300 participants across 1 site.
Detailed Summary
This study is to evaluate the safety and efficacy of Alrex (LE ophthalmic suspension, 0.2%) versus Patanol (olopatadine hydrochloride ophthalmic solution, 0.1%) in the temporary relief of the signs and symptoms of Seasonal Allergic Conjunctivitis (SAC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Allergic Conjunctivitis
CountriesSingapore
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2010
Primary CompletionApr 2011
Study CompletionMay 2011
First PostedSep 2011
TodayJul 2026
First PostedSep 16, 2011
Enrollment StartAug 1, 2010
Primary CompletionApr 1, 2011
Study CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 14.8 years ago
Interventions
Loteprednol etabonate 0.2%drug
1 drop of Alrex 4 times daily (QID) in both eyes at approximately 4 hour intervals for 2 weeks.
Olopatadine 0.1%drug
1 drop of Patanol 2 times daily (BID)at intervals of 6-8 hours or more for 2 weeks.